Results 11 to 20 of about 2,602 (175)

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target-Bound. [PDF]

Chemistry
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Wieske LHE, Bu G, Erdélyi M, Kihlberg J, Gonen T, Danelius ER.   +5 more
europepmc   +2 more sources

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C. [PDF]

Int J Hepatol
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Tawara S, Watanabe A, Yamaguchi J, Omi M, Miyazaki T, Taguchi H, Kiyota R, Yamai T, Kawai S, Inoue T, Yakushijin T.   +10 more
europepmc   +2 more sources

Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis [PDF]

, 2013
Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects ...
Dultz, Georg, Friedrich-Rust, Mireen, Herrmann, Eva, Hofmann, Wolf Peter, Kronenberger, Bernd, Sarrazin, Christoph, Seelhof, Martin, Teuber, Gerlinde, Vermehren, Johannes, Wagner, Michael von, Welker, Martin-Walter, Zeuzem, Stefan   +11 more
core   +10 more sources

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]

, 2015
Importance Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.
Cooper, James, Dore, Gregory J., Everson, Gregory, Freilich, Bradley, Ghesquiere, Wayne, Herring, Robert, Hughes, Eric A., Hézode, Christophe, Kwo, Paul, Lalezari, Jacob, McPhee, Fiona, Muir, Andrew J., Pockros, Paul J., Poordad, Fred, Ramji, Alnoor, Reau, Nancy, Sheikh, Aasim, Stuart, Katherine, Swenson, E. Scott, Thompson, Alexander J., Tran, Albert, Vierling, John, Yang, Rong, Yin, Philip D., Yozviak, Joseph   +24 more
core   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

Creating Designer Engineered Extracellular Vesicles for Diverse Ligand Display, Target Recognition, and Controlled Protein Loading and Delivery

Advanced Science, Volume 10, Issue 34, December 6, 2023., 2023
This study details a comprehensive cell engineering toolbox to genetically modify extracellular vesicles (EV) to enhance EV's ability to target cells of interest, load, and efficiently deliver protein cargo in recipient cells. The findings shed light on the potential of engineered EVs as advanced drug delivery vehicles for targeted and efficient ...
Alena Ivanova, Lukas Badertscher, Gwen O'Driscoll, Joakim Bergman, Euan Gordon, Anders Gunnarsson, Camilla Johansson, Michael J. Munson, Cristiana Spinelli, Sara Torstensson, Liisa Vilén, Andrei Voirel, John Wiseman, Janusz Rak, Niek Dekker, Elisa Lázaro‐Ibáñez   +15 more
wiley   +1 more source

Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelés nélkül 15–25 év alatt májzsugort, májelégtelenséget, májrákot okozhat.
Halász, Tünde, Horváth, Gábor, Hunyady, Béla, Makara, Mihály   +3 more
core   +1 more source

Engineering multiple levels of specificity in an RNA viral vector [PDF]

, 2020
Synthetic molecular circuits could provide powerful therapeutic capabilities, but delivering them to specific cell types and controlling them remains challenging.
Chong, Lucy S., Elowitz, Michael B., Gao, Xiaojing J., Ince, Michaela H., Kim, Matthew S.   +4 more
core   +1 more source